Clinical Data The US FDA lifted a partial clinical hold on Medivation's MDV9300 or pidilizumab for the treatment of hematological malignancies.  A Phase 2 study, that began late 2015, may now proceed and will study pidilizumab on patients with elapsed or refractory diffuse large B-cell lymphoma (DLBCL).  The Company expects to begin enrolling patients in the second half of 2016.